Even companies like Amgen and Novartis, still in early or limited stages in this space, are investing heavily in metabolic disease pipelines, signaling that the race for dominance in obesity and diabetes therapeutics is far from over and will only intensify as global prevalence of these conditions continues to rise
The SELECT trial showed that semaglutide 2.4 mg (Wegovy) reduces cardiovascular risk in adults with established cardiovascular disease and either overweight or obesity, leading to an FDA-approved indication for reducing cardiovascular risk in this population
If you are using this medicine for diabetes or weight-related goals, Managing Ozempic Side Effects can help you prepare practical questions for your prescriber
In the study conducted by Nachvak et al., L-carnitine supplementation significantly increased serum total antioxidant capacity (TAC) and significantly reduced levels of myeloperoxidase (MPO), nitrotyrosine (NT), and high-sensitivity C-reactive protein (hs-CRP) compared to the placebo group
Important, mais intressant